Q4 · MEDICINE
Review
Author: Riaz, Irbaz Bin ; Anwer, Faiz ; Kamal, Muhammad Umar ; Zeeshan, Ali ; Hamadani, Auon Abbas ; Husnain, Muhammad ; Raina, Ammad ; McBride, Ali ; George, Laeth ; Puvvada, Soham ; Rahman, Bushra ; Sipra, Qurat-ul-Ain Riaz ; Hua, Anh ; Zahid, Umar
Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.